Krystal Biotech, Inc. KRYS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $55.93M+8.8% | $51.4M-35.2% | $79.37M+107% | $38.33M+7.3% | $35.73M-21.4% | ||
| $1.52M-2.6% | $1.56M+11.6% | $1.4M+7.7% | $1.3M-7.8% | $1.41M+3.4% | ||
| $13.61M-1.1% | $13.76M+4.6% | $13.15M-6.8% | $14.12M+4.8% | $13.48M+0.9% | ||
| -$58K— | —— | $17.92M+119% | $8.18M+650% | -$1.49M-120% | ||
| $243K-77.0% | $1.06M-77.6% | $4.71M— | —— | $1.4M-78.6% | ||
| $1.02M— | —— | —— | $4.12M+355% | $906K— | ||
| -$6.31M-209% | $5.79M-2.2% | $5.92M— | $0-100% | $3.7M-50.6% | ||
| $1.7M— | —— | $1.35M— | —— | $3.43M-53.0% | ||
| $1.44M+155% | $562K+60.6% | $350K-58.0% | $834K+56.2% | $534K-18.8% | ||
| $136K-52.9% | $289K— | —— | $76K-87.6% | $614K— | ||
| $204K+2.0% | $200K-4.3% | $209K+7.7% | $194K-13.4% | $224K+17.3% | ||
| $80.38M+3.7% | $77.51M+95.4% | $39.66M-24.8% | $52.73M+70.3% | $30.97M-41.4% | ||
| $7.15M+234% | $2.14M+25.5% | $1.7M-10.5% | $1.9M-69.3% | $6.2M+675% | ||
| $160.03M+121% | $72.46M-26.3% | $98.37M-13.6% | $113.9M-17.3% | $137.81M-3.9% | ||
| $103.6M+20.8% | $85.76M-10.5% | $95.79M-9.0% | $105.28M+18.5% | $88.81M+46.8% | ||
| $0— | —— | —— | —— | $435K— | ||
| -$63.58M— | —— | -$4.29M+59.3% | -$10.53M+80.8% | -$54.77M+34.6% | ||
| $6.5M+193% | -$6.97M-288% | $3.71M+107% | $1.8M+22.8% | $1.46M— | ||
| —— | —— | —— | —— | —— | ||
| -$10.46M-167% | $15.67M— | —— | —— | -$12.47M-613% | ||
| -$1.33M— | —— | —— | $1.06M+519% | $171K+129% | ||
| $5.01M-95.2% | $103.7M+167% | $38.78M-13.9% | $45.06M+225% | -$36.1M-24.0% | ||
| $627K-65.1% | $1.8M+9,883% | $18K-99.9% | $13.46M+3,265% | $400K-22.3% | ||
| -$576K+9.6% | -$637K-96.0% | -$325K-135% | $917K+302% | -$453K-165% | ||
| $1.52M-2.6% | $1.56M+11.6% | $1.4M+7.7% | $1.3M-7.8% | $1.41M+3.4% | ||
| $0— | —— | —— | —— | -$31.25M— | ||
| -$6.31M-209% | $5.79M-2.2% | $5.92M— | $0-100% | $3.7M-50.6% | ||
| $12.69M+449% | $2.31M-44.0% | $4.12M-2.6% | $4.23M-60.1% | $10.6M+46.0% | ||
| -$227K-37.6% | -$165K-6.5% | -$155K-27.0% | -$122K+10.3% | -$136K+37.0% | ||
| $1.44M+155% | $562K+60.6% | $350K-58.0% | $834K+56.2% | $534K-18.8% | ||
| $1.7M— | —— | $1.35M— | —— | $3.43M-35.4% | ||
| -$3.37M-247% | $2.29M— | —— | —— | -$457K-147% | ||
| $204K+2.0% | $200K-4.3% | $209K+7.7% | $194K-13.4% | $224K+17.3% | ||
| $529K+30.9% | $404K-68.8% | $1.29M-53.1% | $2.75M+83.4% | $1.5M-8.5% | ||
| $103.6M— | —— | —— | $105.28M+18.5% | $88.81M+46.8% | ||
| $0— | —— | —— | —— | $435K— | ||
| $1.22M-50.2% | $2.44M— | —— | —— | $1.4M+581% | ||
| $0— | —— | —— | —— | $1.8M— | ||
| $73.23M-2.8% | $75.37M+98.6% | $37.96M-25.3% | $50.83M+105% | $24.77M-52.4% | ||
| $73.23M-2.8% | $75.37M+98.6% | $37.96M-25.3% | $50.83M+105% | $24.77M-52.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Krystal Biotech, Inc. generate?
- Krystal Biotech, Inc. (KRYS) generated $250.3M in operating cash flow over the trailing twelve months.
- What is Krystal Biotech, Inc.'s free cash flow?
- After $12.9M of capital expenditures, Krystal Biotech, Inc.'s free cash flow was $237.4M over the trailing twelve months, up 76.3% year over year.
- Where does Krystal Biotech, Inc.'s cash flow data come from?
- Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
